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Background: Carbapenem resistant Enterobacteriaceae is a worldwide threat, with increasing prevalence in many
countries. Restricted usage of higher end antibiotics, especially carbapenem is of great importance in tackling these
super bugs. Purpose of this retrospective study was to analyse the impact of antibiotic stewardship activities on the
prevalence of carbapenem resistant Enterobacteriaceae in our hospital.
Findings: In the first Quarter of 2009, average usage of carbapenem group of antibiotics was 955 vials a month
while in 2010, the usage dropped to 745 vials per month. Carbapenem resistant E.coli rate dropped from 3.7% in
2009 to 1.6% in 2010 and Klebsiella rate reduced from 6% in 2009 to 3.6% in 2010.
Conclusions: Strict antibiotic stewardship strategies in conjunction with good infection control practices are useful
in restricting higher end antibiotic usage and reducing the prevalence of carbapenem resistant Enterobacteriaceae.
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Antimicrobial resistance is a significant global challenge
which every hospital is trying to tackle. “Bad Bugs, No
drugs” is an issue of upmost importance which can ad-
versely affect the health care delivery systems of all
countries [1]. Apollo Speciality hospital is a tertiary care
oncology centre with an active Bone marrow transplant
programme. Oncology patients receiving chemotherapy
are severely immunocompromised, highly vulnerable to
all infections. Higher end antibiotics especially carbape-
nem group is widely recommended and used in oncol-
ogy hospitals. At the same time, resistance to this group
of drugs is increasing in all countries [2-5]. Restriction
of higher end antibiotics especially carbapenem group
needs determination and whole hearted cooperation of
all health care professionals involved in the care of these
immunocompromised patients [6-9].* Correspondence: drghafur@hotmail.com
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Restricted list of higher end antibiotics was prepared
(imipenem, meropenem, ertapenem, doripenem, colistin
and tigecyline) by Infection Control Team in 2007. The
need for a restricted list was discussed with all consul-
tants and junior doctors by multiple circulars and aca-
demic meetings in the hospital involving all specialities.
The importance of antibiotic stewardship and infection
control was stressed upon in departmental meetings and
so whole hearted cooperation from all medical and para-
medical staff was ensured. Regular feed backs on the re-
sistance statistics and antibiotic usage were provided to
all departments. Whenever a restricted higher end anti-
biotic was used, second opinion by Infectious diseases
Consultants within 48 hrs was made mandatory. Clinical
pharmacists provided daily list of restricted antibiotics
and compliance was tracked by the Infection Control
Team. In case of any violation of the policy, the primary
consultant was directly contacted by the Infection Control
Team and if necessary by Medical Superintendent and
documented. The policy was further strengthened in 2008Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion between infection control team and other doctors. In-
fectious disease consultant directly communicated in a
diplomatic and professional way with other consultants;
in case of any difference of opinion on the need of
higher end antibiotic usage (Figure 1, 2, 3). Strict antibiotic
stewardship policy of “Save antibiotics, Save lives” was
implemented with re enforcement of basic infection
control measures.
(a) Isolation precautions were strictly followed. Sign
boards for patients requiring contact isolation either
for an MDR colonisation or infection were displayed
on the doors of all rooms in three languages. A cart
comprising of aprons, masks and gloves were placed
outside the patients’ room and the usage of this was
also strictly monitored.
(b) Compliance to hand washing was regularly
monitored. Infection control nurse would conduct
weekly audits on adherence to hand hygiene and
would give feedback to all relevant departments.
(c) Continuing Medical Education activities were
conducted periodically for all junior doctors,
healthcare workers and nurses with detailed
discussions on all aspects of infection control.
(d) Education of relatives of patients: leaflets on the
importance of infection control measures were
regularly distributed among patients and relatives to
ease any doubts on the need of such strict infection
control measures.
(e) Whenever a specific infection control measure was
implemented, for e.g. Isolating in a single room,Figure 1 Higher end antibiotics daily check list digitally recorded.both patient and relatives were properly counseled
on the need of such special measures to protect the
patient and other patients in the hospital.
(f ) Infection prevention week was conducted during
which our work was reviewed, detailed plan for the
future programmes and activities were made and
they were strictly adhered to. During this week
health care workers and nurses were also awarded
as a token of recognition of their efforts and also to
encourage them.
(g) Infection control committee meetings were held
once in three months, to analyse the resistance
trend, compliance to infection control policy and to
plan future activities. The committee included
representatives of all departments, hospital
management, housekeeping, nursing department,
infection control nurses, quality system, laundry
manager and hospital engineer.
Infection control in the ICU, especially in a hospital
which caters to the need of immunocompromised host
and trauma patient is a great challenge. A dedicated ICU
nurse solely taking care of Infection control was assigned.
This nurse would monitor adherence to the Infection con-
trol practices in the ICU especially compliance to the anti-
biotic policy and various bundle approaches.
Adherence to surgical prophylaxis was the next chal-
lenge requiring a multidisciplinary approach. A dedicated
nurse assigned for this purpose would look into the timing
and choice of the antimicrobial agent, the number of
doses administered and would constantly give a feed back
to the surgeons and management.
Figure 2 Example of a daily check list of higher end antibiotics.
Ghafur et al. Antimicrobial Resistance and Infection Control 2012, 1:29 Page 3 of 4
http://www.aricjournal.com/content/1/1/29Results and Discussion
Due to very vigilant monitoring on the prescription of
higher end antibiotics there was an obvious drop in the
carbapenem usage. In the first Quarter of 2009, average
usage of carbapenem group of antibiotics was 955 vialsFigure 3 Higher end antibiotic usage tracking process.(imipenem 265, meropenem 645, ertapenem 43vials) a
month while in 2010, carbapenem usage dropped to 745
vials (imipenem 185, meropenem 518, ertapenem 42).
Antibiotic usage data available as vials used per month,
DDD(Defined Daily Dose),as it ideally should have been;
still serves the purpose, albeit a crude one, to compare
usage over time; in a hospital where there was no differ-
ence in the bed occupancy over time, especially when the
purpose of the study was not a direct comparison between
carbapenem usage and carbapenem resistance, instead
assessing the performance of a number of interrelated in-
fection control practices. Carbapenem resistant E.coli rate
dropped from 3.7%(of the total number of E.coli isolates
in all specimens) in 2009 to 1.6% in 2010 and carbapenem
resistant Klebsiella rate reduced from 6% in 2009 to 3.6%
in 2010. Extended Spectrum Beta-lactamases producing
E.coli rate increased from 70% to 82%,while Klebsiella
rate reduced from 80 to 75%. As a result of the strict anti-
biotic policy, the adherence to the receipt of first dose of
antibiotic was greater than 95% and adherence to discon-
tinuation of antibiotic post operatively was 80%.
The reduction in the prevalence of carbapenem resistant
Enterobacteriaceae may not be just due to the tightness of
the antibiotic policy but to the improvement in the overall
standard of infection control, as a result of better aware-
ness on the importance of controlling superbugs. This
policy has helped in keeping the carbapenem resistant
Enterobacteriaceae rate lower than the previous year; at a
time when increasing resistance of these bacteria to carba-
penem has been reported from around the world; prompt-
ing World Health Organisation to declare antimicrobial
resistance the most important challenge medical field is
facing today [10].
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single infection control intervention, but does prove that
strict infection control strategies could be effectively
implemented in hospitals in developing countries. Suc-
cess of our campaign has significant implication at na-
tional and international level. All hospitals in South Asia
should follow similar tight antibiotic policy and
infection control measures so that the region can make
significant contribution to the global fight against anti-
microbial resistance. Success of infection control strat-
egies in a few hospitals will only have limited impact in
the overall antimicrobial resistance rate in a country,
unless similar strategies are adopted by all hospitals.
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